{"id":67405,"date":"2026-06-05T13:18:28","date_gmt":"2026-06-05T05:18:28","guid":{"rendered":"https:\/\/flcube.com\/?p=67405"},"modified":"2026-06-05T13:18:28","modified_gmt":"2026-06-05T05:18:28","slug":"biogen-secures-fda-breakthrough-therapy-designation-for-salanersen-in-spinal-muscular-atrophy-once-yearly-aso-with-novel-chemical-structure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67405","title":{"rendered":"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Biogen<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BIIB:NASDAQ\">NASDAQ: BIIB<\/a>) announced it has received <strong>Breakthrough Therapy Designation (BTD)<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for <strong>salanersen<\/strong> (BIIB115) in the treatment of <strong>spinal muscular atrophy (SMA)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>FDA (United States)<\/td><\/tr><tr><td><strong>Designation<\/strong><\/td><td>Breakthrough Therapy Designation (BTD)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Salanersen (BIIB115) \u2013 intrathecally administered antisense oligonucleotide (ASO)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Spinal muscular atrophy (SMA)<\/td><\/tr><tr><td><strong>Designation Date<\/strong><\/td><td>Week of 05 Jun 2026<\/td><\/tr><tr><td><strong>Origin<\/strong><\/td><td>Discovered by Ionis Pharmaceuticals, licensed by Biogen in 2018<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Salanersen (BIIB115) \u2013 <strong>antisense oligonucleotide (ASO)<\/strong> administered intrathecally<\/li>\n\n\n\n<li><strong>Primary Target:<\/strong> <strong>SMN2 pre-mRNA splicing correction<\/strong><\/li>\n\n\n\n<li><strong>Mechanism:<\/strong> Increases production of <strong>survival motor neuron (SMN) protein<\/strong> by modulating SMN2 gene splicing<\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> <strong>Novel chemical structure<\/strong> conferring high potency<\/li>\n\n\n\n<li><strong>Dosing Advantage:<\/strong> Potentially enables <strong>once-yearly administration<\/strong>, representing a significant improvement over current SMA therapies requiring frequent dosing<\/li>\n\n\n\n<li><strong>Development Partnership:<\/strong> Originally discovered by <strong>Ionis Pharmaceuticals<\/strong>, exclusively licensed by Biogen in 2018 strategic collaboration<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-significance-amp-market-context\" class=\"wp-block-heading\">Clinical Significance &amp; Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Current SMA Landscape<\/th><th>Salanersen Differentiation<\/th><\/tr><\/thead><tbody><tr><td><strong>Available Therapies<\/strong><\/td><td>Nusinersen (Spinraza\u00ae): Intrathecal, loading doses + maintenance every 4 months<br>Zolgensma\u00ae: IV gene therapy, one-time but limited to young children<br>Risdiplam (Evrysdi\u00ae): Daily oral administration<\/td><\/tr><tr><td><strong>Patient Burden<\/strong><\/td><td>Frequent hospital visits, lumbar punctures, or daily medication adherence<\/td><\/tr><tr><td><strong>Market Size<\/strong><\/td><td>Approximately 10,000-15,000 SMA patients in US, 30,000+ globally across all age groups<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications-for-biogen\" class=\"wp-block-heading\">Strategic Implications for Biogen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>SMA Franchise Expansion:<\/strong> Builds on Biogen&#8217;s established SMA leadership with Spinraza\u00ae, creating a potential next-generation option<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Once-yearly dosing could significantly disrupt the current SMA treatment paradigm and capture market share from existing therapies<\/li>\n\n\n\n<li><strong>Revenue Opportunity:<\/strong> Potential to command premium pricing given superior convenience and potentially enhanced efficacy profile<\/li>\n\n\n\n<li><strong>Pipeline Validation:<\/strong> Demonstrates continued success of Biogen&#8217;s partnership with Ionis Pharmaceuticals in neurological disorders<\/li>\n\n\n\n<li><strong>Global Strategy:<\/strong> BTD accelerates development timeline and supports parallel regulatory discussions with EMA and other global agencies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding regulatory designations, clinical development, and commercial expectations for salanersen. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[351,993],"class_list":["post-67405","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-biogen","tag-nasdaq-biib"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for salanersen (BIIB115) in the treatment of spinal muscular atrophy (SMA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67405\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure\" \/>\n<meta property=\"og:description\" content=\"Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for salanersen (BIIB115) in the treatment of spinal muscular atrophy (SMA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67405\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:18:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67405#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67405\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure\",\"datePublished\":\"2026-06-05T05:18:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67405\"},\"wordCount\":345,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biogen\",\"NASDAQ: BIIB\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67405#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67405\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67405\",\"name\":\"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T05:18:28+00:00\",\"description\":\"Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for salanersen (BIIB115) in the treatment of spinal muscular atrophy (SMA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67405#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67405\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67405#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure - Insight, China&#039;s Pharmaceutical Industry","description":"Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for salanersen (BIIB115) in the treatment of spinal muscular atrophy (SMA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67405","og_locale":"en_US","og_type":"article","og_title":"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure","og_description":"Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for salanersen (BIIB115) in the treatment of spinal muscular atrophy (SMA).","og_url":"https:\/\/flcube.com\/?p=67405","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:18:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67405#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67405"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure","datePublished":"2026-06-05T05:18:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67405"},"wordCount":345,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biogen","NASDAQ: BIIB"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67405#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67405","url":"https:\/\/flcube.com\/?p=67405","name":"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T05:18:28+00:00","description":"Biogen (NASDAQ: BIIB) announced it has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA) for salanersen (BIIB115) in the treatment of spinal muscular atrophy (SMA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67405#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67405"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67405#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biogen Secures FDA Breakthrough Therapy Designation for Salanersen in Spinal Muscular Atrophy \u2013 Once-Yearly ASO with Novel Chemical Structure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67405","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67405"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67405\/revisions"}],"predecessor-version":[{"id":67407,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67405\/revisions\/67407"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67405"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67405"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67405"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}